## CRSP: CRISPR Therapeutics AG - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($48.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next**
- Source: ts2.tech | 20260101T185900 | Somewhat-Bearish | Relevance: 100%
- CRISPR Therapeutics (CRSP) stock entered 2026 after closing down 1.4% at $52.44 on the last trading day of 2025, with U.S. markets closed for New Year's Day. Investors are keenly watching the rollout of its gene-editing therapy, Casgevy, and future updates from partner Vertex Pharmaceuticals. Key events include Vertex's presentation at the J.P. Morgan Healthcare Conference and CRISPR's upcoming Q4 earnings report.

**2. Chardan maintains a buy recommendation on CRISPR Therapeutics AG (CRSP)**
- Source: MSN | 20251231T190919 | Bullish | Relevance: 100%
- This article states that Chardan has reiterated its buy recommendation for CRISPR Therapeutics AG (CRSP). No further details about the reasons for the rating or specific financial data are provided in the snippet.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-23 | Needham | $80 | $80 | 0% |
| 2025-12-23 | Citizens | $86 | $86 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-23 | Needham | reit | Buy |
| 2025-12-23 | Citizens | reit | Market Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 7 ($4.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- ARK Investment Manag: 10.3% (-3.9%)
- Blackrock Inc.: 7.4% (+16.2%)
- Capital Internationa: 5.9% (+1.0%)
- Orbis Allan Gray Ltd: 5.2% (+80.2%)
- State Street Corpora: 4.2% (+22.5%)

### Key Risks

1. Insider selling cluster: $4.0M in recent transactions.
2. High short interest (25.8%, 10.4 days to cover): squeeze risk or crowded bearish bet.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Balance sheet: strong liquidity (16.2x), low leverage (D/E 0.17). Revenue growth strong at 1916% YoY. Insider selling cluster ($4.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $5.1B |
| Beta | 1.73 |
| 52W Range | $30.04 - $78.48 |
| Short Interest | 25.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.21 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from -3.1% to -1.6% (+1.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.6pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.8%) - potential reversal signal. Underperforming sector by 3.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.04x) but short-term weakness (below SMA20). RSI neutral at 44. OFD pattern: +STN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.63% (CS: 16) | Neutral |
| RSI_14 | 44.3 | Neutral |
| MACD Histogram | -0.25 | Bearish |
| vs SMA20 | 0.961x | Below |
| vs SMA50 | 0.953x | Below |
| vs SMA200 | 1.042x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $53.77
- **Stop Loss:** $48.55 (9.7% risk)
- **Target:** $58.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 275
- **Position Value:** $14,786.75
- **Portfolio %:** 14.79%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.29 | $-1.17 | +9.2% |
| 2025Q2 | $-1.40 | $-1.29 | +7.8% |
| 2025Q1 | $-1.28 | $-1.58 | -23.8% |
| 2024Q4 | $-1.19 | $-0.44 | +62.9% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*